A prospective, post-marketing, single-center, study to evaluate safety and performance of the Evermine 50-50Î¼m Everolimus-Eluting Coronary Stent System (EES) in the treatment of patients with de novo native coronary artery lesions - Evermine 50 EES â?? 1 BGM

Meril Life Sciences Pvt Ltd0 个研究点目标入组 250 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.The subject must be at least 18 years of age at the time of signing the informed consent.
•2.The subjectâ??s legally authorized representative agrees to the subjectâ??s participation in this study and signs the informed consent form.
•3.The subject who agree to participate in the study.
•4.Only Evermine 50 EES stent(s) is (are) implanted during the index procedure.
•5.The subject whose coronary artery is suitable for implantation of Evermine 50 EES.
•6.Female subjectâ??s of childbearing potential who does not plan pregnancy for up to 2 years from the date of index procedure. For a female subject of childbearing potential a pregnancy test must be performed with negative results at screening visit.
•7.Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 2 years from the date of index procedure.
•8.Subject agrees not to participate in any other investigational or invasive clinical study for a period of 2 years from the date of index procedure

•1.The inability to obtain an informed consent.
•2.Subject with known hypersensitivity or allergies to aspirin, heparin, Everolimus, polymer lactide, Cobalt-chromium metal and glycolide antiplatelet drugs (clopidogrel, prasugrel etc).
•3.Female subject with known pregnancy or who are lactating at the time of screening

发起方

Meril Life Sciences Pvt Ltd